These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

753 related articles for article (PubMed ID: 17928874)

  • 1. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer.
    Riezebos-Brilman A; Walczak M; Regts J; Rots MG; Kamps G; Dontje B; Haisma HY; Wilschut J; Daemen T
    Gene Ther; 2007 Dec; 14(24):1695-704. PubMed ID: 17928874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization.
    Daemen T; Riezebos-Brilman A; Regts J; Dontje B; van der Zee A; Wilschut J
    Antivir Ther; 2004 Oct; 9(5):733-42. PubMed ID: 15535411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
    Daemen T; Pries F; Bungener L; Kraak M; Regts J; Wilschut J
    Gene Ther; 2000 Nov; 7(21):1859-66. PubMed ID: 11110419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7.
    Daemen T; Regts J; Holtrop M; Wilschut J
    Gene Ther; 2002 Jan; 9(2):85-94. PubMed ID: 11857066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition.
    de Mare A; Lambeck AJ; Regts J; van Dam GM; Nijman HW; Snippe H; Wilschut J; Daemen T
    Gene Ther; 2008 Mar; 15(6):393-403. PubMed ID: 18004406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice.
    Riezebos-Brilman A; Regts J; Freyschmidt EJ; Dontje B; Wilschut J; Daemen T
    Gene Ther; 2005 Sep; 12(18):1410-4. PubMed ID: 15843807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterologous prime-boost immunizations with a virosomal and an alphavirus replicon vaccine.
    Walczak M; de Mare A; Riezebos-Brilman A; Regts J; Hoogeboom BN; Visser JT; Fiedler M; Jansen-Dürr P; van der Zee AG; Nijman HW; Wilschut J; Daemen T
    Mol Pharm; 2011 Feb; 8(1):65-77. PubMed ID: 20825215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in mice.
    Lyons JA; Sheahan BJ; Galbraith SE; Mehra R; Atkins GJ; Fleeton MN
    Gene Ther; 2007 Mar; 14(6):503-13. PubMed ID: 17167497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic, therapeutic and anti-metastatic effects of an HPV-16mE6Delta/mE7/TBhsp70Delta fusion protein vaccine in an animal model.
    Qian X; Lu Y; Liu Q; Chen K; Zhao Q; Song J
    Immunol Lett; 2006 Feb; 102(2):191-201. PubMed ID: 16242781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant Semliki Forest virus vaccine vectors: the route of injection determines the localization of vector RNA and subsequent T cell response.
    Colmenero P; Berglund P; Kambayashi T; Biberfeld P; Liljeström P; Jondal M
    Gene Ther; 2001 Sep; 8(17):1307-14. PubMed ID: 11571567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector.
    Juillard V; Villefroy P; Godfrin D; Pavirani A; Venet A; Guillet JG
    Eur J Immunol; 1995 Dec; 25(12):3467-73. PubMed ID: 8566039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
    Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI
    Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of rapidly growing K-BALB and CT26 mouse tumours using Semliki Forest virus and its derived vector.
    Smyth JW; Fleeton MN; Sheahan BJ; Atkins GJ
    Gene Ther; 2005 Jan; 12(2):147-59. PubMed ID: 15372069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmentation of alphavirus vector-induced human papilloma virus-specific immune and anti-tumour responses by co-expression of interleukin-12.
    Riezebos-Brilman A; Regts J; Chen M; Wilschut J; Daemen T
    Vaccine; 2009 Jan; 27(5):701-7. PubMed ID: 19041356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor.
    Jin HS; Park EK; Lee JM; NamKoong SE; Kim DG; Lee YJ; Jun HJ; Han BD; Bae SM; Ahn WS
    Gynecol Oncol; 2005 May; 97(2):559-67. PubMed ID: 15863160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of T cell competition in the induction of cytotoxic T lymphocyte activity during viral vector-based immunization regimens.
    Lambeck AJ; Nijman HW; Hoogeboom BN; Regts J; de Mare A; Wilschut J; Daemen T
    Vaccine; 2010 Jun; 28(26):4275-82. PubMed ID: 20434555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of human lung carcinoma cell growth by apoptosis induction using Semliki Forest virus recombinant particles.
    Murphy AM; Morris-Downes MM; Sheahan BJ; Atkins GJ
    Gene Ther; 2000 Sep; 7(17):1477-82. PubMed ID: 11001367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining T-cell vaccination and application of agonistic anti-GITR mAb (DTA-1) induces complete eradication of HPV oncogene expressing tumors in mice.
    Hoffmann C; Stanke J; Kaufmann AM; Loddenkemper C; Schneider A; Cichon G
    J Immunother; 2010; 33(2):136-45. PubMed ID: 20145549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPV16-specific cytotoxic T lymphocyte responses are detected in all HPV16-positive cervical cancer patients.
    Valdespino V; Gorodezky C; Ortiz V; Kaufmann AM; Roman-Basaure E; Vazquez A; Berumen J
    Gynecol Oncol; 2005 Jan; 96(1):92-102. PubMed ID: 15589586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.